REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 29/03/2019 >View issuer details

2020.07.06 | 22:30 | Permanent Information Releases / Notification of availability

puce Availability of the Pre-quarterly Results Communication - HTML (w)

2020.07.06 | 22:30 | Permanent Information Releases / Notification of availability

puce Mise en ligne du document « Pre-quarterly Results Communication » - HTML (w)

2020.07.02 | 22:30 | Permanent Information Releases / General Company News

puce Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients - HTML (w)

2020.07.02 | 22:30 | Permanent Information Releases / General Company News

puce Sanofi et Regeneron font le point sur l’essai de phase III consacré à Kevzara® (sarilumab) aux États-Unis chez des patients COVID-19 - HTML (w)

2020.06.23 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients - HTML (w)

2020.06.23 | 07:00 | Permanent Information Releases / General Company News

puce Journée virtuelle dédiée à la R&D de Sanofi : présentation des capacités et plateformes technologiques ainsi que l’expertise dans les voies de signalisation des maladies, pour le développement de médicaments ayant le potentiel de transforme - HTML (w)

2020.06.23 | 06:59 | Permanent Information Releases / General Company News

puce Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas - HTML (w)

2020.06.23 | 06:59 | Permanent Information Releases / General Company News

puce Sanofi et Translate Bio élargissent leur collaboration pour développer des vaccins à ARNm contre toutes les catégories de maladies infectieuses - HTML (w)

2020.06.19 | 22:46 | Share History / Voting Rights and Number of Shares

puce Sanofi: Information concerning the total number of voting rights and shares - May 2020 - HTML (w)

2020.06.19 | 22:46 | Share History / Voting Rights and Number of Shares

puce Sanofi : Informations relatives au nombre total de droits de vote et d’actions - Mai 2020 - HTML (w)

2020.06.19 | 15:00 | Permanent Information Releases / General Company News

puce Sanofi announces positive long-term efficacy and safety data for fitusiran from interim analysis of Phase 2 extension study in people with hemophilia A and B, with or without inhibitors - HTML (w)

2020.06.19 | 15:00 | Permanent Information Releases / General Company News

puce Sanofi présente les données intermédiaires positives de sécurité et d’efficacité à long terme de l’étude de prolongation de phase II du fitusiran chez des personnes atteintes d’hémophilie A ou B, avec ou sans inhibiteurs - HTML (w)

2020.06.19 | 13:30 | Permanent Information Releases / General Company News

puce Dupixent® (dupilumab) approved in China for adults with moderate-to-severe atopic dermatitis - HTML (w)

2020.06.19 | 13:30 | Permanent Information Releases / General Company News

puce Dupixent® (dupilumab) approuvé en Chine pour le traitement de la dermatite atopique modérée à sévère de l’adulte - HTML (w)

2020.06.16 | 14:00 | Permanent Information Releases / General Company News

puce Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2911